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Summary
Objective: Central nervous system (CNS) aspergillosis is a life-threatening disease that has had a
published mortality of >80%. Little is known about this serious infection in the pediatric
population. We conducted this study to analyze characteristics of CNS aspergillosis in infants
and children.
Methods: The English literature was reviewed and all CNS aspergillosis cases in patients younger
than 18 years of age were analyzed.
Results: Ninety cases were recorded up to June 2005. Themedian age of the patients was 9 years,
ranging from 18 days to 18 years (15.6% younger than 1 year). CNS aspergillosis most commonly
presented as brain abscess(es), either single or multiple. While prematurity was the predominant
underlying condition among infants, leukemia was the most frequent underlying disease in
children. Aspergillus fumigatus was isolated from 75.5% of the cases. The overall mortality in
published cases was 65.4%. In multivariate analysis, surgical treatment was independently
associated with survival.
Conclusion: CNS aspergillosis in infants and children predominantly presents as brain abscess(es)
and has significantly better outcome compared to published adult data. The findings of this
systematic review could assist future investigations for improved outcome of this life-threatening
infection in pediatric patients.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.§ These data were presented in part at the 23rd Annual Meeting of
the European Society of Pediatric Infectious Diseases, Valencia,
Spain, May 2005 (Abstract 316, p. 160).
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While novel agents such as amphotericin B lipid formulations,
newer azoles and echinocandins have entered the armamen-
tarium of antifungal drugs, invasive aspergillosis (IA) remains
a medical challenge due to its very high mortality.1,2 Invasive
aspergillosis predominantly occurs in immunocompromised
hosts, such as those with hematological malignancies,Published by Elsevier Ltd. All rights reserved.
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enital or acquired immunodeficiency, as well as use of
corticosteroids and other immunosuppressive drugs.3 Other
situations that predispose to invasive fungal infections
including aspergillosis have been found to be intravascular
catheters, premature birth, serious burns, abdominal surgery
and intravenous drug addiction.4,5
Dissemination of Aspergillus spp is relatively common,
with the central nervous system (CNS) being one of the most
frequent sites of IA after the lungs.6 The brain and subar-
achnoid space are protected from fungal pathogens by ana-
tomic and functional barriers, but under special conditions
and immune system abnormalities, fungal pathogens breach
these barriers. CNS symptoms eventually develop in one-half
of patients with disseminated aspergillosis and are the pre-
senting feature in one-third of them.7 The extent of gross
neuropathologic disease ranges from subtle abscesses,
extensive hemorrhage, focal purulent meningitis and bland
infarctions to massive hemorrhagic necrosis causing hernia-
tion and death. Despite perceived advances in early diag-
nosis, initiation of treatment and newer antifungal agents,
CNS aspergillosis remains a devastating opportunistic infec-
tion, and the prognosis is discouragingly poor in adults.8
Invasive aspergillosis in infants and children may exhibit
differences from cases in adults, such as less specific findings
and greater difficulties in early diagnosis and antifungal
treatment.9 Little is known about CNS aspergillosis in this
group of hosts and whether there are any differences from
adults. Thus, we conducted a review of all such cases that
occurred during childhood that are reported in the literature.
Our goal was to review and analyze the pediatric cases in
order to determine whether any factor(s), including age,
underlying disease, pathological type of and species causing
CNS aspergillosis, relationship with other sites of IA, diag-
nostic methods, and antifungal therapy or adjunctive treat-
ment, affect the outcome of this lethal infection.
Literature review and methods
Relevant case reports and series of CNS aspergillosis pub-
lished in the English literature were retrieved using ‘asper-
gillosis’ and ‘central nervous system’ as either a keyword or
MeSH (medical subject heading) with the limitation ‘all child:
0—18 years’ from searches of the PubMed bibliographic
database (US National Library of Medicine, Bethesda, MD,
USA) for the period of 1950 to June 2005. All the articles
found by this means were systematically reviewed and a
master database was constructed. The references cited in
the above articles were screened for additional cases of CNS
infections due to Aspergillus spp in patients less than 18 years
of age.
For this analysis, diagnosis of a definite case of Aspergillus
CNS infection required evidence of Aspergillus in cerebrosp-
inal fluid (CSF) or brain biopsy specimens as either positive
culture or histology showing fungal elements. Cases with
positive CNS cytology or histology and a positive culture
for Aspergillus from other site(s) were classified as definite
CNS aspergillosis without positive CNS fungal cultures. Cases
of patients who had an indication of CNS infection in com-
puted tomography (CT) or magnetic resonance imaging (MRI)
scans, plus a definite Aspergillus infection at body sites other
than the CNS were classified as probable CNS aspergillosis. Inaddition, the presence of galactomannan antigen or a posi-
tive polymerase chain reaction (PCR) test in CSF, or CNS
tissue, in the presence of an abnormal CSF showing inflam-
mation in an immunocompromised host, also defined a prob-
able case of Aspergillus CNS infection.
Specifically, a definite diagnosis of Aspergillus brain
abscess required one or more lesions with a hypodense
central area and a peripheral uniform ring enhancement
following the injection of contrast material attributable to
a fungal infection. A variable hypodense area of brain edema
as shown by CT or MRI may have surrounded this enhanced
ring.10 Aspergillus spp should have been recovered from a
culture of aspiration or biopsy of a specimen obtained from
the abscess or should have been seen in a biopsy specimen but
not cultured or should have indirect evidence of Aspergillus
infection. Such indirect evidence may have included galac-
tomannan antigen or PCR tests used to define Aspergillus
meningitis, or be definite or probable at another site in the
body (e.g., invasive pulmonary aspergillosis). For such cate-
gorization in other sites the criteria constructed by the
European Organization for Research and Cancer Treatment
Infectious Diseases Group in collaboration with the National
Institute of Allergy and Infectious Diseases Mycoses Study
Group were used.11
Microsoft Excel (XP Professional) software (Redmond, WA,
USA) was used to develop a database of categorical and
continuous variables. Variables included in the database were
demographics such as year of publication of case(s), age and
sex of patient(s) and underlying diseases. In addition, diag-
nosticmethods (CT,MRI, galactomannan assay, PCR, culture or
histology), pre- or post-mortem diagnosis, type of CNS infec-
tion (meningitis, encephalitis, brain abscess, others), prior or
concomitant IA affecting other sites of the body, species of
Aspergillus isolated, antifungal drugs administered, neurosur-
gery, adjunctive immunotherapy (hematopoietic growth fac-
tors, other cytokines, granulocyte transfusions), and outcome
were included. The statistical program GraphPad Instat
(Graphpad Inc., San Diego, CA, USA) was used for the analysis
of the results. Statistical evaluation of differences in propor-
tions and calculation of odds ratio (OR) and 95% confidence
intervals (CI) were performed by Fisher’s exact test. A p value
of <0.05 indicated statistical significance.
Univariate analysis was conducted using the Statistical
Package for the Social Sciences for Windows (version 11.5;
SPSS Inc., Chicago, IL, USA) to determine the association
between potential protective or risk factors (surgery, anti-
fungal therapy, underlying disease, age and year of publica-
tion) and survival. All variables with a p value of <0.20 on
univariate analysis as well as variables with a biologically
plausible relationship were considered for inclusion in a
multivariate model. Multivariate analysis was performed
using logistic regression.
Results
Seventy-four cases were found in searches of the PubMed
bibliographic database as case reports or series. Twenty-two
additional cases were found, after the references cited in the
above articles were further screened. Six cases were
excluded since the authors did not analyze pediatric cases
of CNS aspergillosis separately.12 In parallel, a few additional
cases (unspecified number) of pediatric patients aged
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was performed, so they were also excluded from the analy-
sis.13,14 Finally, a total of 90 CNS aspergillosis cases were
analyzed. These published cases were for patients younger
than 18 years, and for the time period up to June 2005.
The first reported case that was included occurred in 1955
and was published in 1986.15 It was the case of a 2759 g-birth
weight neonate who had suffered from an Aspergillus brain
abscess. The infant presented with early signs of sepsis
requiring intravenous therapy with antibiotics, but infection
of the brain due to Aspergillus spp occurred 3 weeks later and
led to death 30 days later. The cases of CNS aspergillosis in
children older than 1 year are summarized in Table 116—58 and
the cases in infants (less than 1 year of age) in Table 2.59—61
Demographic and clinical characteristics
The demographic, clinical and therapeutic characteristics of
all the pediatric cases with CNS aspergillosis are shown in
Table 3. Fourteen of these patients (14/90, 15.6%) were
infants with a median age of 30 days. The median age of
older children was 11 years.
Underlying disease
Among infants with an underlying condition reported, pre-
maturity was predominant followed by staphylococcal pneu-
monia with septicemia, and hepatic failure. Among children
(>1 year) with an underlying condition reported, leukemia
was the predominant underlying condition, followed by solid
tumors, liver transplantation, chronic granulomatous disease
(CGD), hematological disorders (e.g., aplasia), and various
other conditions. The most common type of leukemia asso-
ciated with CNS aspergillosis was acute lymphoblastic leu-
kemia (ALL), which was significantly more frequent than
acute myelogenous leukemia (AML; including acute non-lym-
phoblastic leukemia (ANLL)) and chronic myelogenous leu-
kemia (CML) (Table 3 footnote c, p < 0.05).
Means of diagnosis and microbiology
Seventy-seven cases were classified as definite according to
the definitions mentioned in the Methods section (with or
without positive cultures from CNS). Histology and autopsy
were the most frequent means of establishing the diagnosis in
these cases. In 55 definite cases, complete post- or pre-
mortem diagnostic data were available. Stereotactic biopsy
cultures from abscesses obtained by craniotomy or percuta-
neous aspiration of the cerebral lesions grewAspergillus spp in
22 (40%) cases. In two (3.6%) cases the identification of CNS
aspergillosis was established by cultures of CSF.15,29,60,61 In 31
(56.4%) cases CNS aspergillosis was diagnosed post-mortem
and in 24 (43.6%) cases diagnosis was established pre-mortem.
Among 53 cases in which Aspergillus isolates were identi-
fied to the species level, the most frequent species isolated
was Aspergillus fumigatus followed by Aspergillus flavus,
Aspergillus terreus and Aspergillus niger (Table 3).
Pathology
The most common pathological types of CNS aspergillosis
were single or multiple brain abscesses throughout the cere-brum, cerebellum, basal ganglia and brainstem. Vasculitis
and meningoencephalitis or encephalitis due to Aspergillus
spp were also found in a few cases (Table 3). The brain
lesions consisted of typical necrotizing parenchymal lesions
with vascular invasion and secondary hemorrhages, occasion-
ally associated with meningoencephalitis. Hemorrhages most
commonly presented as hemorrhagic infarcts, subarachnoid
hemorrhages or intracerebral hemorrhages.
Thirty-six cases of CNS aspergillosis presented with addi-
tional non-CNS sites of IA. The most common non-CNS
affected sites among these cases were the lungs and sinuses,
while a number of other sites were additionally involved
(Table 3). Multi-organ IA with CNS involvement (three or
more organs infected) was found in three cases. In one case,
a simultaneous infection of the CNS, lungs, kidney and liver
was found; in another case, simultaneous infection was found
in the CNS, lungs and liver; and in a third case, simultaneous
infection involved the CNS, lung, heart and bone.
Treatment
From a total of 90 reviewed cases with CNS aspergillosis, 42
(46.7%) patients received treatment versus 17 (18.9%) that
did not ( p < 0.01). In the remaining 31 patients data were
not available.
The most frequently used drug for the treatment of CNS
aspergillosis was amphotericin B, either deoxycholate or lipid
formulations of amphotericin B, followed by azoles in some
cases. Specifically, among 42 cases with antifungal drug
administration reported, amphotericin B (AMB) was used in
all cases. Deoxycholate amphotericin B (DAMB) was used as
an initial treatment in 35 (83.3%), alone in 13 (31%), com-
bined with flucytosine, rifampin, or with an Aspergillus-
active azole, itraconazole, in 11 (26.2%), and combined with
rifampin plus flucytosine or plus an Aspergillus-active azole,
itraconazole, in four cases (9.5%). In one case DAMB was
combined with fluconazole. In two cases, the primary treat-
ment with DAMB was switched to itraconazole plus flucyto-
sine, and in one case to itraconazole alone. In addition,
primary DAMB in one case was switched to amphotericin B
lipid complex (ABLC) and then to DAMB, in one case to
liposomal amphotericin B (LAMB) and then itraconazole, in
one case to LAMB plus itraconazole, and in one case to LAMB
plus voriconazole. In one infant case and in four cases in
children older than 1 year, rifampin was added to DAMB. Lipid
formulations of amphotericin B (in most cases LAMB) were
used in 11 (26.2%) cases, alone in two (4.8%), and with an
Aspergillus-active azole in three cases (7.1%; two itracona-
zole, one voriconazole). In one case LAMB was combined with
fluconazole. Voriconazole was used as monotherapy after
discontinuation of DAMB and then LAMB in one case with
favorable outcome.58
Surgical debridement appears to have a determinant role
in the treatment of CNS infections due to Aspergillus spp
especially of brain abscesses. Surgery was used in 25/69
(36.2%) cases in which information about neurosurgery was
provided. On the other hand, granulocyte colony-stimulating
factor (G-CSF) was used in 3/42 (7.1%) cases with antifungal
therapy reported, interferon-gamma (IFN-g) in two (4.8%),
granulocyte-macrophage colony-stimulating factor (GM-CSF)
in two (4.8%), and white blood cell transfusions in one (2.4%)
case.
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Table 1 Cases of CNS aspergillosis in children older than 1 year sorted by year of diagnosis
Patient Reference Year of
publication
Sex/age
(years)
Underlying disease Type of CNS infection Antifungal therapy Surgery Outcome
1 16 1962 NA/7 No Brain abscess DAMB Yes Survived
2 17 1966 F/8 Bacterial infection)
antibiotics—
corticosteroid treatment
Brain abscess No No Died
3 18 1971 M/5 ALL Massive brain abscess No No Died
4 19 1975 F/4 NA Meningeal and intracerebral
arteries invasion
NA NA Died
5 19 1975 M/8 NA Brain abscess NA NA Died
6 19 1975 F/14 NA Mid-dorsal block invasion NA Yes Survived
7 20 1978 M/18 No Aspergillosis in the arterial wall No No Died
8 21 1979 M/14 Cellular immunodeficiency Brain abscess No No NA
9 22 1980 M/7 ALL Necrotic brain abscess No No Died
10 23 1982 M/12 ALL Brain abscess DAMB + 5FC +
inhaled natamycin
Yes Survived
11 24 1982 F/15 Subacute hepatic necrosis Multiple brain abscesses No No Died
12 25 1983 M/7 Congenital basophil
agranulocytocis
Multiple brain abscesses DAMB +
intraventricular DAMB
No Died
13 26 1985 M/9 Hepatic failure Multiple brain abscesses No No Died
14 26 1985 M/14 ALL Multiple brain abscesses No No Died
15 27 1987 M/4 CGD Epidural abscess DAMB + 5FC Yes Survived
16 28 1988 M/10 ALL (T-Cell) Infarction with invasion DAMB No Died
17 29 1989 M/5 Liver transplantation Meningoencephalitis NA No Died
18 29 1989 F/11 Liver transplantation Meningoencephalitis NA No Died
19 29 1989 M/18 Liver transplantation Meningoencephalitis NA No Died
20 30 1991 M/11 CGD Intracerebral lesions DAMB) itraconazole +
5FC + WBCTx
No Survived
21 31 1993 F/2 CGD Brain abscess NA Yes NA
22 32 1993 F/6 Pre-B-ALL + BMT Multiple brain abscesses DAMB) itraconazole Yes Survived
23 33 1993 M/16 Heart transplantation Occipital and parietal infracts
due to Aspergillus
NA NA NA
24 33 1993 M/18 Liver transplantation Multiple brain abscesses NA NA NA
25 33 1993 F/18 Liver transplantation Occipital hemorrhagic infracts NA NA NA
26 34 1994 M/10 ALL Multifocal cerebral aspergillosis DAMB) itraconazole + 5FC No Survived
27 35 1995 M/2 ALL Multiple brain abscesses DAMB) LAMB) oral
itraconazole
Yes Survived
28 36 1995 M/2 HIV Brain abscess DAMB NA Died
29 36 1995 M/12 HIV Encephalopathy No No Died
30 37 1996 F/17 Prior (15 months) surgical
treatment for an ependymoma
Brain abscess DAMB + itraconazole Yes Died
31 38 1997 F/14 ALL + HSCT Multiple brain abscesses DAMB) ABLC) DAMB No Survived
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32 39 1997 F/18 BMT for aplastic anemia Brain abscess LAMB + itraconazole Yes Survived
33 40 1998 NA/14 ALL Aspergillosis in the vessel wall NA NA NA
34 40 1998 NA/14 AML Paravertebral mass, cord infarct
due to Aspergillus
NA NA NA
35 40 1998 F/15 ALL Multifocal purulent leptomeningeal
exudates, abscess in cord
DAMB NA NA
36 41 1998 NA/<18 CML Multiple brain abscesses NA No Died
37 41 1998 NA/<18 PNET Multiple brain abscesses NA Yes Died
38 41 1998 NA/<18 ALL Multiple brain abscesses NA No Died
39 41 1998 NA/<18 Glioma Brain abscess NA Yes Survived
40 41 1998 NA/<18 AML Multiple brain abscesses NA No Survived
41 41 1998 NA/<18 Glioma Brain abscess NA Yes Survived
42 41 1998 NA/<18 AML Brain abscess NA Yes Died
43 42 1999 F/10 Neurosurgery for
craniopharyngioma
Intracerebral hemorrhage due to
Aspergillus invasion
No Yes Died
44 43 1999 F/11 ALL Vasculitis + multiple brain abscesses DAMB Yes Died
45 44 1999 M/17 ANLL NA DAMB No Died
46 44 1999 M/9 ANLL NA No No Died
47 44 1999 F/16 ANLL NA DAMB + rifampin + 5FC Yes Died
48 44 1999 F/14 ALL NA DAMB + rifampin + 5FC +
GM-CSF
No Died
49 44 1999 F/11 MDS + BMT NA DAMB + rifampin + 5FC No Died
50 44 1999 F/3 ANLL NA DAMB No Died
51 44 1999 M/16 ALL NA DAMB + 5FC No Died
52 44 1999 M/16 ALL + BMT NA DAMB + rifampin +
itraconazole
No Died
53 44 1999 F/14 Hodgkin’s lymphoma NA DAMB No Died
54 44 1999 F/1
(13 months)
Neuroblastoma NA No No Died
55 44 1999 M/18 ANLL + BMT NA DAMB No Died
56 44 1999 M/2 ANLL + BMT NA No No Died
57 44 1999 M/3 ALL NA DAMB No Died
58 44 1999 F/15 MDS + BMT NA DAMB + 5FC No Died
59 45 1999
(diagnosis in 1992)
M/17 ALL NA DAMB + 5FC Yes Survived
60 45 1999
(diagnosis in 1992)
M/16 ALL NA Fluconazole) DAMB +
5FC + G-CSF
No Died
61 46 2000 F/2 ALL (B-cell) Brain abscess LAMB + fluconazole +
G-CSF
Yes Survived
62 47 2000 M/4 Hurler disease NA NA NA Died
63 47 2000 F/5 Fanconi anemia NA NA NA Died
64 47 2000 M/11 Aplastic anemia NA NA NA Survived
65 48 2001 F/5 Cardiomyopathy Multiple brain abscesses NA NA NA
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Table 1 (Continued )
Patient Reference Year of
publication
Sex/age
(years)
Underlying disease Type of CNS infection Antifungal therapy Surgery Outcome
66 48 2001 F/5 Crouzon syndrome,
post-surgical infection
Multiple brain abscesses NA NA Survived
67 49 2001 M/11 CGD Brain abscess DAMB + itraconazole +
IFN-g
Yes Survived
68 50 2001 F/16 AML Spinal epidural abscess DAMB Yes Survived
69 51 2002 F/10 Cardiomyopathy, heart
transplantation
Cerebral artery-focal
Aspergillus vasculitis
No No Died
70 52 2002 M/11 Alveolar rhabdomyosarcoma
) chemotherapy
Multiple brain abscesses LAMB No Survived
71 53 2003 M/7 Craniocerebral injury Brain abscess DAMB) LAMB +
itraconazole
Yes Survived
72 54 2003 F/11 AML + BMT Cortical vessels thrombosis
by Aspergillus invasion
DAMB + fluconazole No Died
73 55 2003 M/2 Corticosteroid-resistant
nephrotic syndrome
Encephalitis LAMB No Died
74 56 2003 M/12 Alopecia areata)
corticosteroid treatment
Brain abscess LAMB) itraconazole Yes Survived
75 57 2004 F/3 ALL Orbitocerebral aspergillosis LAMB + 5FC) LAMB +
voriconazole + G-CSF +
IFN-g + GM-CSF
No Survived
76 58 2006 M/8 CGD Multiple brain abscesses DAMB) LAMB)
voriconazole
No Survived
CNS, central nervous system; M, male; F, female; NA, not available; AMB, amphotericin B; DAMB, deoxycholate amphotericin B; LAMB, liposomal amphotericin B; ABLC, amphotericin B lipid
complex; 5FC, flucytosine; WBCTx, white blood cell transfusion; ALL, acute lymphoblastic leukemia; ANLL, acute non-lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic
myelogenous leukemia; PNET, primitive neuroectodermal tumor; MDS,myelodysplastic syndrome; BMT, bonemarrow transplantation; CGD, chronic granulomatous disease; HSCT, hematopoietic
stem cell transplantation; HIV, human immunodeficiency virus; IFN-g, interferon-gamma; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte—monocyte colony-stimulating
factor.
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Table 2 Cases of CNS aspergillosis in infants sorted by year of diagnosis
Patient Reference Year of publication Sex/age
(days)
Underlying disease Type of CNS
infection
Antifungal therapy Surgery Outcome
1 15 1986 (diagnosis in 1955) NA/30 Staphylococcal sepsis Brain abscess No No Died
2 15 1986 (diagnosis in 1957) NA/25 Broad spectrum antibiotics Brain abscess No No Died
3 15 1986 (diagnosis in 1963) NA/51 Escherichia coli sepsis Brain abscess No No Died
4 15 1986 (diagnosis in 1985) NA/27 Prematurity Brain abscess DAMB + 5FC +
intraventricular
DAMB
Yes Survived
5 59 1991 M/98 Liver transplantation Brain abscess DAMB + rifampin +
intraventricular
DAMB
Yes Survived
6 60 1998 (diagnosis in 1963) F/51 Prematurity, erythroblastosis
fetalis, recurrent bacteremia
NA NA NA Died
7 60 1998 (diagnosis in 1963) F/59 Prematurity NA NA NA Died
8 60 1998 (diagnosis in 1966) F/73 Diarrhea, dehydration NA NA NA Died
9 60 1998 (diagnosis in 1973) M/65 Staphylococcal septicemia,
pneumonia
Diffuse
meningoencephalitis
NA NA Died
10 60 1998 (diagnosis in 1979) F/18 Hepatic failure NA NA NA Died
11 60 1998 (diagnosis in 1988) F/24 Hepatic failure NA NA NA Died
12 60 1998 (diagnosis in 1989) F/22 Malnutrition NA NA NA Died
13 60 1998 (diagnosis in 1992) M/29 Cyanotic heart disease Multiple brain
abscesses
DAMB Yes Survived
14 61 2000 M/30 Aplastic cutis congenita at the
scalp vertex + hypoplastic left
heart syndrome
Multiple brain
abscesses
LAMB + 5FC No Survived
CNS, central nervous system; M, male; F female; NA, not available; DAMB, deoxycholate amphotericin B; LAMB, liposomal amphotericin B; 5FC, flucytosine.
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Table 3 Characteristics of reviewed cases of CNS aspergil-
losis in childhood (N = 90)
Age of all patients (median, range) 9 years
(18 days—18 years)
Age of infants (n = 14) 30 days
(18 days—98 days)
Age of older children (n = 76) 11 years
(1 year—18 years)
Male sex (n = 76) 41 (53.9%)
Underlying disease in infantsa (n = 14)
Prematurity 3 (21.4%)
Staphylococcal infectionb 2 (14.3%)
Hepatic failure 2 (14.3%)
Underlying disease in patients >1 yeara (n = 73)
Leukemiac 33 (45.2%)
Solid tumors 7 (9.6%)
Liver transplantation 5 (6.8%)
CGD 5 (6.8%)
Diagnosis of definite cases (n = 55d)
Post-mortem 31 (56.4%)
Pre-mortem 24 (43.6%)
Biopsy cultures 22 (40%)
Blood/CSF cultures 2 (3.6%)
Aspergillus species identity (n = 53)
Aspergillus fumigatus 40 (75.5%)
Aspergillus flavus 10 (18.9%)
Aspergillus terreus 2 (3.8%)
Aspergillus niger 1 (1.8%)
Type of Aspergillus infectiona (n = 65)
Brain abscess(es) 45 (69.2%)
Vasculitis 10 (15.4%)
Meningoencephalitis/encephalitis 5 (7.7%)
Non-CNS sites of Aspergillus infectiona (n = 36)
Lungs 22 (61.1%)
Sinuses 4 (11.1%)
Kidneys 2 (5.6%)
Liver 2 (5.6%)
Other sites 6 (16.7%)
Antifungal therapy (n = 59)
No treatment 17 (28.8%)
Antifungal treatment 42 (71.2%)
Amphotericin B 42 (100%)
(Deoxycholate
amphotericin Be)
35
(Lipid formulations of
amphotericin Bf)
11
Voriconazole 2 (4.8%)
Surgerya (intralesional
debridement, n = 69)
25 (36.2%)
CNS, central nervous system; CGD, chronic granulomatous dis-
ease; CSF, cerebrospinal fluid.
a Most frequent entities.
b Pneumonia/sepsis.
c Acute lymphoblastic leukemia 21/33 (63.6%), acute myelo-
genous leukemia (including acute non-lymphoblastic leukemia)
and chronic myelogenous leukemia 12/33 (36.4%) (p < 0.05).Mortality of CNS aspergillosis
The overall mortality rate in this cohort of published pedia-
tric cases of CNS aspergillosis was 65.4% (Table 4). However,
the overall mortality rate of the cases reported after 1990
(with known year of diagnosis) was 39.5%, whilst that of the
cases reported before 1990 was 82.8% ( p = 0.0004). Specifi-
cally, cases that occurred in children >1 year old and pub-
lished after 1990 had a significantly lower mortality rate than
cases reported before 1990 ( p = 0.021). Similarly, cases that
occurred in infants and published after 1990 had a signifi-
cantly lower mortality rate than cases reported before 1990
( p = 0.01).
There was no difference between the periods after 1998
and 1990—1998. While after 1998 overall mortality was 38.9%
(7/18 cases), between 1990 and 1998 it was 40% (8/20 cases),
and before 1990 it was 82.8% (24/29 cases). Various other
time breakpoints did not show significant differences on
mortality rates.
When single case reports were separated from case series
(defined as containing at least two originally reported cases),
the overall mortality rate of case series was 71.2%. The
mortality rate of the case series reported after 1990 was
52.9%, whilst that of the case series reported before 1990 was
90.5% ( p = 0.023) (Table 4).
When the mortality was determined only for the smaller
number of cases that were diagnosed pre-mortem, there was
an insignificant trend of lower mortality rate after combined
surgical and antifungal treatment as compared to antifungal
drugs alone and no neurosurgery. Similarly, there was a trend
for highermortality induced by A. flavus than by A. fumigatus
in the small number of cases with pathogen identification to
the species level (Table 4).
Before 1990, although the outcome was reported, data on
antifungal therapy were available only in some cases. After
1990 the antifungal therapy data were available in 18 survi-
vors. In this period, DAMB was the initial therapy in 12
survivors (66.7%) and LAMB in six (33%). Amphotericin B plus
an Aspergillus-active azole either as initial therapy or sec-
ondary therapy was used in four patients (22.2%; three
itraconazole (two plus LAMB, one plus DAMB), one voricona-
zole (one plus LAMB)).
Fifty-six infants and children with all data included in the
original publication were enrolled in a univariate analysis ofd Number of definite cases with post- or pre-mortem data
available.
e Alone in 13 cases (31%), combined with flucytosine, rifampin,
or with an Aspergillus-active azole, itraconazole, in 11 (26.2%)
and combined with rifampin plus flucytosine or plus an Aspergil-
lus-active azole, itraconazole, in four (9.5%). The primary treat-
ment with deoxycholate amphotericin B (DAMB) was switched in
two cases to itraconazole plus flucytosine, in one cases to itra-
conazole alone, in one case to amphotericin B lipid complex and
switched again to DAMB, in one case to liposomal amphotericin B
(LAMB) and then itraconazole, in one case to LAMB plus itraco-
nazole, and in one case to LAMB plus voriconazole. In one infant
and in four children older than 1 year, DAMB was used in combina-
tion with rifampin.
f Alone in two (4.8%) patients, combined with Aspergillus-
active azoles like itraconazole (2) or voriconazole (1) in three
(7.1%) patients.
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Table 4 Mortality of CNS aspergillosis
Overall mortality rate (n = 81) 53 (65.4%)
Prior to 1990 (n = 29) 24 (82.8%)a
Infants (<1 year) (n = 11) 10 (90.9%)b
Children (>1 year) (n = 18) 14 (77.8%) c
After 1990d (n = 38)e 15 (39.5%)a
Infants (n = 3) 0 (0%)b
Children (n = 35) 15 (42.9%) c
Mortality rate in case series reports (n = 59) 42 (71.2%) f
Prior to 1990 (n = 21) 19 (90.5%)g
Infants (n = 11) 10 (90.9%)h
Children (n = 10) 9 (90%) i
After 1990 (n = 17)e 9 (52.9%)g
Infants (n = 1) 0 (0%)h
Children (n = 16) 9 (56.3%) i
Mortality rate in single case reports (N = 29) 11 (37.9%) f
Prior to 1990 (n = 8) 5 (62.5%) j
Infants (n = 0) —
Children (n = 8) 5 (62.5%)k
After 1990 (n = 21) 6 (28.6%) j
Infants (n = 2) 0 (0%)
Children (n = 19) 6 (31.6%)k
Mortality rate in cases diagnosed pre-mortem
With antifungal therapy only (n = 10) 3 (30%) l
With antifungal therapy and surgical
treatment (n = 16)
2 (12.5%) l
Mortality rate in cases according to Aspergillus spp
A. fumigatus (n = 38) 20 (52.6%)m
A. flavus (n = 10) 8 (80%)m
n, number of patients with individual data reported.
a Between mortality rates prior to 1990 and after 1990, OR:
0.14, 95% CI: 0.042—0.43, p = 0.0004.
b Between mortality rates prior to 1990 and after 1990 in
infants, OR: 0.02, 95% CI: 0.0007—0.63, p = 0.01.
c Between mortality rates prior to 1990 and after 1990 in
children, OR: 0.21, 95% CI: 0.059—0.78, p = 0.021.
d After 1990 the antifungal therapy data were available for 18
survivors. In this period, deoxycholate amphotericin B (DAMB)
was the initial therapy in 12 survivors (66.7%) and liposomal
amphotericin B (LAMB) in six (33%). Amphotericin B plus an
Aspergillus-active azole either as initial therapy or secondary
therapy was used in four (22.2%) patients (three itraconazole
(two plus LAMB, one plus DAMB), one voriconazole (one plus
LAMB)).
e Data coming from cases with known year of diagnosis (cases
from Ref. 44 are not included).
f Between mortality rates based on single case reports and case
series reports, OR: 0.25, 95% CI: 0.097—0.63, p = 0.005.
g Betweenmortality rates (based on case series reports) prior to
1990 and after 1990, OR: 0.12, 95% CI: 0.02—0.68, p = 0.023.
h Betweenmortality rates (based on case series reports) prior to
1990 and after 1990 in infants, OR: 0.048, 95% CI: 0.001—1.8,
p = 0.17.
i Betweenmortality rates (based on case series reports) prior to
1990 and after 1990 in children, OR: 0.14, 95% CI: 0.015—1.41,
p = 0.099.
j Betweenmortality rates (based on single case reports) prior to
1990 and after 1990, OR: 0.24, 95% CI: 0.04—1.34, p = 0.198.
k Betweenmortality rates (based on single case reports) prior to
1990 and after 1990 in children, OR: 0.28, 95% CI: 0.049—1.56,
p = 0.21.factors potentially associated with survival of the patients
(Table 5). Surgery and antifungal therapy were found to be
significant protective factors, whereas age >1 year or leu-
kemia as underlying disease were not associated with altered
survival. Furthermore, among 49 patients older than 1 year,
surgery and the antifungal therapy were significant factors
( p < 0.01) associated with survival of the patients (data not
shown). However, of these factors only surgery was indepen-
dently associated with survival when included in multivariate
analysis models (OR: 10, 95% CI: 2—50, p = 0.0048).
Discussion
In this study we analyzed the characteristics of a large
number of pediatric cases of CNS aspergillosis published as
single case reports, small series, or as part of larger series.
We found that most cases presented as single or multiple
brain abscesses, with A. fumigatus being the most frequent
cause. The predominant underlying condition was prematur-
ity among infants and leukemia among children. Together
with antifungal therapy, surgery was associated with signifi-
cantly improved outcome.
Historically, the mortality rate of CNS aspergillosis was
exceeding 90% and even approaching 100% in adult patients
with acute leukemia with or without bone marrow transplan-
tation; this decreased to no lower than approximately 70%
even in the last published study after administration of
voriconazole with or without surgery.2,8,62 Such data, how-
ever, were lacking for pediatric patients. The better outcome
of CNS aspergillosis in infants and children that we found
(39.5% mortality in cases published after 1990) reflects the
overall more favorable prognosis of IA in children than in
adults.48,60 This discrepancy may be related to different
underlying diseases in the two age groups and other co-
existing conditions as well as other age-related differences
not clearly defined at present. For example, the better
outcome in children may be related to the generally better
prognostic outlook of their underlying conditions (i.e., acute
leukemia). Publication bias (i.e., cases of non-surviving
patients possibly not being ‘reportable’ during the last dec-
ade) may have potentially underestimated mortality in our
analysis. However, the same publication bias applies for
similarly published adult cases. Thus, the mortality differ-
ence between pediatric patients and adults is most probably
true.
This comprehensive analysis of all pediatric cases of CNS
aspergillosis published in the English literature up to June
2005 indicates a substantial decrease in mortality from 82.8%
before 1990 to less than half (39.5%) in cases published after
1990. This dramatic decrease in infants and children may
have been due to the introduction of amphotericin B lipid
formulations and Aspergillus-active azoles as well as most
importantly to the developments for earlier diagnosis of CNS
aspergillosis. Strengthening the validity of this finding, mor-
tality was also decreased from 90.5% before 1990 to 52.9%l Between mortality rates of cases that were diagnosed pre-
mortem and had surgical treatment combined with antifungal
treatment and cases that were managed with antifungal drugs
only and no neurosurgery, OR: 3, 95% CI: 0.4—22, p = 0.34.
m Between mortality rates of cases that A. fumigatus and
A. flavus was isolated, OR: 0.28, 95% CI: 0.05—1.5, p = 0.16.
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Table 5 Potential protective factors for survival of patients during univariate analysisa
Characteristic Survival
Yes (n = 22) No (n = 34) OR 95% CI p Value
Surgery (%) 68 12 16 4.06—63.65 <0.0001
Antifungal therapy (%) 100 53 40 2.25—715 <0.0001
Age (more than 1 year) (%) 82 91 0.436 0.087—2.17 0.415
Leukemia as underlying disease (%) 41 50 0.69 0.23—2.047 0. 589
a Fifty-six infants and children with all data available.after 1990 ( p = 0.023) when single case reports, where pub-
lication bias is believed to be a larger problem than in cases
series reports, were excluded (Table 4). While only a trend of
decreased mortality rate in the published cases that had
combined surgical and antifungal drug treatment (12.5%) was
observed compared to antifungal drugs alone (30%, p = 0.34),
in cases with localized lesions of CNS, such as brain abscesses,
neurosurgery may be associated with a favorable outcome of
the patients.
Aspergillus spp can induce unusual clinical features
caused by unique sites of CNS involvement. Specifically,
basilar meningitis, myelitis, sino-orbital disease, carotid
artery invasion, epidural abscesses, massive hemorrhagic
necrosis with herniation as the cause of death, isolated or
subtle intracranial disease, and mycotic aneurysms can be
caused by Aspergillus spp. In addition, hemorrhagic necrosis
as the primary macroscopic feature of CNS aspergillosis has
been emphasized in some studies.33,48 In this review, single or
multiple brain abscesses were the most common sites of CNS
aspergillosis and were found in 45/65 (69.2%) cases.
Aspergillus spp are primarily respiratory pathogens, and
the lungs constitute the main portal of entry before disse-
mination. It is important to note that in most cases of CNS
aspergillosis the portal of entry and the route for Aspergillus
spp remains unspecified and is a subject of speculation.
However, in 45% (9/20) of the reviewed cases with data
available, CNS aspergillosis was the result of dissemination
from the respiratory tract. In a few cases, CNS constitutes the
primary site involved in aspergillosis.
Underlying disease seems to be a very important factor
for the development of CNS aspergillosis. Prematurity is a
risk factor for neonatal IA suggesting that immature neo-
natal anatomical and immune defense systems probably
play a role in disease acquisition.60 Supporting this notion,
in this review we found that in infants, prematurity was
the predominant underlying disease in 21.4% of reported
cases. Among three infants with prematurity as underlying
disease and gestational age mentioned, gestational age
ranged from 31 to 32 weeks; there was no apparent trend
of difference in mortality according to the gestational age.
In addition, in neonates catheter-related infection is the-
oretically possible, but this cannot be documented by
blood culture in most of the cases. In adults, CNS asper-
gillosis is more often associated with immunosuppressive
therapy.7,48 One report suggested that premature infants
exhibit higher risk to present with CNS aspergillosis than
infants receiving immunosuppressive drugs.15 Our finding
that staphylococcal infection followed prematurity as
underlying disease is likely to be due to undiagnosed
CGD in these infants.Our study demonstrated that the most common underlying
diseases associated with CNS aspergillosis in children older
than 1 year are hematological malignancies, with themajority
of patients having leukemia, most commonly ALL followed by
AML.The incidenceofprovenorprobable invasiveaspergillosis
is greater in children with AML (27.7%) than in children with
ALL (2%);45 however, AML accounts for only about 15—20% of
cases of childhood leukemia and ALL for about 75%.63
In the children with leukemia, the major risk factor for
developing CNS aspergillosis is severe neutropenia secondary
to chemotherapy.2 Neutropenia and corticosteroids may
synergistically act to depress natural host defenses.64 While
there was no specific data in all the cases with regard to
neutropenia, we can infer that most children with leukemia
and IA developed the infection during neutropenia. In con-
trast, patients with CGD as underlying disease did not usually
have neutropenia as risk factor for IA. In patients with other
underlying conditions such as premature neonates and liver
transplantation patients, information about neutropenia was
not always given. The meta-analytic character of the study
did not allow us to collect all these data.
Solid organ transplantation is also a significant predispos-
ing condition, illustrating the importance of immunosuppres-
sion for the development of CNS aspergillosis. Some
investigators have found that in this population, the majority
of CNS aspergillosis occurred within the first 3 months after
transplantation, which is the most critical period for IA. Liver
transplant recipients were reported to have earlier onset of
symptoms compared with other transplant recipients.
Increased incidence for CNS aspergillosis can be observed
after the first year of transplantation during chronic rejec-
tion and/or retransplantation during intense immunosuppre-
sion.33,65
This systematic review of the previously published cases
shows that in agreement with the fact that A. fumigatus is
the most common isolate obtained in 70—90% of cases of IA in
immunocompromised patients, this species is also the most
frequent cause of CNS aspergillosis.9,48,66 Of note, A. flavus
constitutes the second most common species, having been
isolated from 18.9% of cases with reported data. The
observed higher mortality induced by A. flavus was not
significant.
Despite recent advances in non-invasive surrogate mar-
kers of many diseases, radiological evaluation remains the
cornerstone of diagnosing IA and CNS aspergillosis.54,67
Unfortunately, in 56.4% (31/55) of CNS aspergillosis cases
reported, diagnosis was established only at autopsy (22 cases
before and nine after 1990). New antigen tests for the early
diagnosis of IA, such as the galactomannan ELISA assay, have
been plagued by lower sensitivity and specificity in certain
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tomannan assay for the diagnosis of CNS aspergillosis has
been reported,70 but warrants further investigations.
Amphotericin B has been the mainstay of medical treat-
ment for both suspected and proven CNS aspergillosis in
childhood during the last decades. DAMB appears to be well
tolerated in infants <3 months without significant nephro-
toxicity.60,71 However, in older patients poor tolerability
often leads to the use of other Aspergillus-active antifungal
agents, such as lipid formulations of amphotericin B, itra-
conazole andmore recently voriconazole. To date, it has not
been established whether itraconazole or lipid formulations
of amphotericin B have superior efficacy to DAMB.62,72
However, some patients refractory to, or intolerant of DAMB
have responded to itraconazole or to lipid formulations of
amphotericin B. Due to the retrospective nature of our
review the issue of dosing of antifungal agents could not
be addressed.
The fact that colony-stimulating factors, such as G-CSF and
GM-CSF as well as cytokines, such as IFN-g, have been admi-
nistered to only few pediatric patients with CNS aspergillosis
does not permit us to drawany definitive conclusions about the
potential role of adjunctive immunotherapy in such patients.
However, it is reasonable to speculate that restoration or
augmentation of immune responses in these patients would
be useful, and these strategies deserve additional study.73
Recently, voriconazole treatment has been reported to
improve outcome of CNS aspergillosis from historical survival
rates of <10%1,62 to a rate of 31% in a cohort of 81 previously
studied cases including a few pediatric patients.8 Among six
such cases of pediatric patients with ages ranging from
9 months to 15 years treated with voriconazole, three had
complete or partial response, one remained in a stable
condition and two patients died.12 Since the authors of this
report did not analyze pediatric cases of CNS aspergillosis
separately, we could not include these children in our study. A
few additional cases of pediatric patients aged between 12
and 18 years, treated with voriconazole, are also included in
two other studies,13,14 but again no separate analysis was
performed. Indeed, the findings of this systematic review of
published pediatric CNS aspergillosis cases could assist future
investigations for improved outcome of this life-threatening
infection.
There are some limitations to this study due to the fact
that the conclusions may be wrong if the cases analyzed
are not a representative sample due to publication bias.
Thus, early cases (1970s and 1980s) may have been
reported because of their uniqueness regardless of out-
come, whereas cases reported in the subsequent decade
(1990s) may have been published rather with a focus on
therapeutic success. In order to confront the publication
bias we could potentially include only reports with a
minimum number of cases. However, since CNS aspergillo-
sis is a rare disease we would exclude most of the data on
this entity. Therefore, we preferred to use the single
case reports for demographic analysis, but we excluded
them from the analysis of the effect of publication year on
the mortality. In addition, concerning the association of
neurosurgery and favorable outcome, it might be the
case that those patients deemed likely to do well
received surgery whereas the very sick and ‘hopeless’
patients were not considered appropriate for surgery.Obviously, a randomized study is not appropriate and
feasible in these patients, a problem inherent also in other
recent studies.8
In conclusion, despite its limitations this review suggests
that the outcome of CNS aspergillosis in infants and children
is better than in adults and may have been further improved
after the introduction of antifungal agents with better ther-
apeutic profile and the use of better diagnostic modalities.
The recent introduction of novel Aspergillus-active azoles
coupled with efforts for early and more accurate diagnosis of
IA in young patients69 may further improve the outcome of
this life-threatening infection.
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